Page last updated: 2024-08-25

bexarotene and Lung Neoplasms

bexarotene has been researched along with Lung Neoplasms in 41 studies

Research

Studies (41)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	1 (2.44)	18.2507
2000's	25 (60.98)	29.6817
2010's	14 (34.15)	24.3611
2020's	1 (2.44)	2.80

Authors

Authors	Studies
Aleiwi, B; Carapellucci, S; Ellsworth, E; Krieger-Burke, T; Leal, AS; Liby, KT; Lockwood, B; Moerland, JA; Reich, LA; Zhang, D	1
Ai, X; Lu, S; Mao, F; Shen, S; Shentu, Y; Wang, J	1
Bhogal, JS; Carapellucci, S; Ibrahim, S; Jurutka, PW; Leal, AS; Liby, KT; Marshall, PA; Raban, S; Shahani, PH; Sporn, MB; Wagner, CE; Zhang, D	1
Chhatwani, L; Jacobs, CD; Lopez-Anaya, A; Padda, SK; Wakelee, HA; Zhou, L	1
Chen, G; Chen, K; Fu, S; Jia, L; Jiang, X; Li, H; Li, Y; Liu, X; Ren, Y; Wang, L; Wang, S; Wu, C; Yang, J	1
Chen, L; Guo, H; Liu, H; Liu, Y; Meng, X; Rong, J; Wang, Y; Zhang, J	1
Andersen, JB; Black, CC; Dmitrovsky, E; Dragnev, K; Feng, Q; Galimberti, F; Guo, Y; Hassel, BA; Liu, X; Memoli, V; Sekula, D; Sempere, LF; Shah, SJ	1
Lubet, RA; Wang, Y; Wen, W; Yi, Y; You, M; Zhang, Z	1
Chen, DR; Chen, R; Liu, P; Lubet, R; Pan, J; Wang, Y; You, M; Zhang, J; Zhang, Q	1
Friedrich, MJ	1
Busch, AM; Cyrus, J; Dmitrovsky, E; Dragnev, KH; Erkmen, CP; Freemantle, SJ; Galimberti, F; Johnstone, D; Kurie, JM; Liu, X; Ma, T; Memoli, V; Nugent, W; Rigas, JR; Seltzer, M; Tsongalis, GJ; Waxman, S	1
Dziewanowska, ZE; Hermann, TW; Luo, W; Malo, N; Marschke, KB; Meglasson, MD; Negro-Vilar, A; Ng, SC; Sanders, JM; Schork, NJ; Tooker, P; Zapala, MA; Zhang, J	1
Casto, BC; Pereira, MA	1
Chu, Q; Jacobs, CD; Lopez-Anaya, A; Rodon, J; Rowinsky, EK; Takimoto, CH; Wakelee, HA	1
Chu, Q; Dunlop, D; Hao, D; Jacobs, CD; Leighl, N; Lopez-Anaya, A; Middleton, G; Ramlau, R; Rodon, J; Rowinsky, EK; Takimoto, CH; Wakelee, HA; Zatloukal, P	1
Dunlop, D; Hao, D; Jacobs, CD; Leighl, N; Lopez-Anaya, A; Middleton, G; Ramlau, R; Wakelee, HA; Zatloukal, P	1
Alden, C; Blumenschein, G; Davis, SE; Herbst, R; Hong, WK; Kim, E; Lee, JJ; Lippman, S; Liu, S; Stewart, D; Tang, XM; Tsao, AS; Wistuba, I	1
Farol, LT; Hymes, KB	1
Bissonnette, RP; Cooke, TA; Corpuz, MR; Lamph, WW; Negro-Vilar, A; Prudente, RY; Yen, WC	1
Dragnev, KH; Rigas, JR	1
Dmitrovsky, E; Dragnev, KH; Ma, Y; Petty, WJ; Rigas, JR	1
Bissonnette, RP; Fan, B; Hermann, TW; Lamph, WW; Negro-Vilar, A; Roegner, K; Tooker, P; Yen, WC	1
Tyagi, P	1
Bedor, M; Bisaccia, S; Doyle, LA; Edelman, MJ; Hausner, P; Kalra, K; Kendall, J; Smith, R	1
Jia, D; Lubet, RA; Wang, D; Wang, Y; Yao, R; You, M; Zhang, Z	1
Biddle, A; Desai, NB; Dmitrovsky, E; Dragnev, KH; Memoli, V; Petty, WJ; Rigas, JR; Shah, S	1
Alyaqoub, FS; Gunning, WT; Kramer, PM; Liu, Y; Lubet, RA; Nines, R; Pereira, MA; Steele, VE	1
Nandan, R	1
Corpuz, MR; Lamph, WW; Negro-Vilar, A; Prudente, RY; Yen, WC	1
Corssmit, EP; Liu, YY; Morreau, HA; Pereira, AM; Romijn, JA; Smit, JW; Stokkel, MP	1
Chen, X; Ding, Y; Fu, J; Huang, D; Li, H	1
Bolejack, V; Crowley, J; Ekstrand, B; Ghalie, R; Govindan, R; Jaunakais, D; Kennedy, P; Sandler, A; Schwartzberg, L; Williams, C	1
Black, CC; Dmitrovsky, E; Dragnev, KH; Hermann, T; Lewis, LD; Memoli, V; Negro-Vilar, A; Nugent, WC; Petty, WJ; Rigas, JR; Shah, SJ	1
Pereira, AM; Romijn, JA; Smit, JW; Stokkel, MP; Visser, TJ	1
Hermann, TW; Negro-Vilar, A; Ng, SC; Tooker, P; Yen, WC	1
Alyaqoub, FS; Liu, Y; Lubet, RA; Pereira, MA; Steele, VE; Tao, L	1
Blumenschein, GR; Dziewanowska, ZE; Gatzemeier, U; Jotte, RM; Khuri, FR; Le Treut, J; Miller, WH; Negro-Vilar, A; Sun, SL; von Pawel, J; Zhang, JK	1
Dziewanowska, ZE; Gottfried, M; Jassem, J; Negro-Vilar, A; Negro-Vilar, R; Orlov, SV; Pereira, JR; Rahal, S; Ramlau, R; Schwarzenberger, P; Temperley, G; Zatloukal, P; Zhang, JK	1
Bengtson, EM; Rigas, JR	1
Bailly, C; Formstecher, P; Lansiaux, A	1
Figlin, RA; Fox, N; Gralla, RJ; Hong, WK; Huyghe, MR; Kean, Y; Khuri, FR; Munden, R; Reich, SD; Rigas, JR; Shin, DM	1

Reviews

4 review(s) available for bexarotene and Lung Neoplasms

Article	Year
Bexarotene: a clinical review. Expert review of anticancer therapy, 2004, Volume: 4, Issue:2 Topics: Anticarcinogenic Agents; Bexarotene; Breast Neoplasms; Clinical Trials as Topic; Humans; Lung Neoplasms; Lymphoma, T-Cell, Cutaneous; Neoplasms; Skin Neoplasms; Tetrahydronaphthalenes	2004
Emerging role of rexinoids in non-small cell lung cancer: focus on bexarotene. The oncologist, 2005, Volume: 10, Issue:1 Topics: Anticarcinogenic Agents; Antineoplastic Combined Chemotherapy Protocols; Bexarotene; Carcinoma, Non-Small-Cell Lung; Cell Division; Cell Proliferation; Clinical Trials as Topic; Humans; Lung Neoplasms; Tetrahydronaphthalenes; Treatment Outcome	2005
Nonclassical retinoids and lung carcinogenesis. Clinical lung cancer, 2005, Volume: 6, Issue:4 Topics: Anticarcinogenic Agents; Antineoplastic Combined Chemotherapy Protocols; Bexarotene; Carcinoma, Non-Small-Cell Lung; Cyclins; ErbB Receptors; Humans; Lung Neoplasms; Protein-Tyrosine Kinases; Receptors, Retinoic Acid; Retinoids; Tetrahydronaphthalenes; Ubiquitin	2005
New oral chemotherapeutic agents for lung cancer. Drugs, 1999, Volume: 58 Suppl 3 Topics: Administration, Oral; Animals; Antineoplastic Agents; Bexarotene; Biphenyl Compounds; Clinical Trials as Topic; Humans; Lung Neoplasms; Organic Chemicals; Organoplatinum Compounds; Phenylbutyrates; Tetrahydronaphthalenes; Topotecan; Vinblastine; Vinorelbine	1999

Trials

16 trial(s) available for bexarotene and Lung Neoplasms

Article	Year
Phase I and pharmacokinetic study of bexarotene in combination with gefitinib in the third-line treatment of non-small-cell lung cancer: brief report. Anti-cancer drugs, 2013, Volume: 24, Issue:7 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bexarotene; Carcinoma, Non-Small-Cell Lung; Cohort Studies; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; Tetrahydronaphthalenes; Treatment Outcome	2013
Bexarotene plus erlotinib suppress lung carcinogenesis independent of KRAS mutations in two clinical trials and transgenic models. Cancer prevention research (Philadelphia, Pa.), 2011, Volume: 4, Issue:6 Topics: Aged; Animals; Antineoplastic Combined Chemotherapy Protocols; Bexarotene; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cyclin D1; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Immunoblotting; Immunoenzyme Techniques; Lung Neoplasms; Male; Mice; Mice, Transgenic; Middle Aged; Mouth Mucosa; Mutation; Necrosis; Neoplasm Recurrence, Local; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Salvage Therapy; Survival Rate; Tetrahydronaphthalenes; Treatment Outcome; Tumor Cells, Cultured	2011
A phase I pharmacokinetic study of bexarotene with paclitaxel and carboplatin in patients with advanced non-small cell lung cancer (NSCLC). Cancer chemotherapy and pharmacology, 2012, Volume: 69, Issue:3 Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Bexarotene; Carboplatin; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Female; Humans; Hypolipidemic Agents; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Retinoid X Receptors; Tetrahydronaphthalenes	2012
The effect of bexarotene on atorvastatin pharmacokinetics: results from a phase I trial of bexarotene plus chemotherapy in patients with advanced non-small cell lung cancer. Cancer chemotherapy and pharmacology, 2012, Volume: 69, Issue:2 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Atorvastatin; Bexarotene; Carcinoma, Non-Small-Cell Lung; Drug Administration Schedule; Drug Interactions; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Hypertriglyceridemia; Lung Neoplasms; Male; Metabolic Clearance Rate; Middle Aged; Pyrroles; Tetrahydronaphthalenes; Treatment Outcome	2012
A phase I pharmacokinetic study of bexarotene with vinorelbine and cisplatin in patients with advanced non-small-cell lung cancer (NSCLC). Cancer chemotherapy and pharmacology, 2012, Volume: 69, Issue:3 Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bexarotene; Carcinoma, Non-Small-Cell Lung; Cisplatin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Female; Humans; Hypolipidemic Agents; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Retinoid X Receptors; Tetrahydronaphthalenes; Vinblastine; Vinorelbine	2012
Clinical outcomes and biomarker profiles of elderly pretreated NSCLC patients from the BATTLE trial. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2012, Volume: 7, Issue:11 Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bexarotene; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Piperidines; Prognosis; Quinazolines; Retrospective Studies; Salvage Therapy; Sorafenib; Survival Rate; Tetrahydronaphthalenes	2012
Bexarotene in combination with chemotherapy fails to prolong survival in patients with advanced non-small-cell lung cancer: results from the SPIRIT I and II trials. Clinical lung cancer, 2005, Volume: 7, Issue:1 Topics: Anticarcinogenic Agents; Antineoplastic Combined Chemotherapy Protocols; Bexarotene; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Survival Analysis; Tetrahydronaphthalenes; Treatment Outcome; Vinblastine; Vinorelbine	2005
Phase II trial of the novel retinoid, bexarotene, and gemcitabine plus carboplatin in advanced non-small-cell lung cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, Aug-20, Volume: 23, Issue:24 Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Bexarotene; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Hypertriglyceridemia; Lung Neoplasms; Male; Middle Aged; Survival Rate; Tetrahydronaphthalenes; Treatment Outcome	2005
Bexarotene and erlotinib for aerodigestive tract cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, Dec-01, Volume: 23, Issue:34 Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bexarotene; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; Cell Survival; Cyclin D1; Digestive System Neoplasms; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Female; Head and Neck Neoplasms; Humans; Hypertriglyceridemia; Lung Neoplasms; Male; Middle Aged; Mouth Mucosa; Protein Kinase Inhibitors; Quinazolines; Sequence Analysis, DNA; Tetrahydronaphthalenes; Treatment Outcome; Tumor Cells, Cultured	2005
Bexarotene increases uptake of radioiodide in metastases of differentiated thyroid carcinoma. European journal of endocrinology, 2006, Volume: 154, Issue:4 Topics: Adult; Aged; Bexarotene; Carcinoma, Papillary; Cell Differentiation; Female; Humans; Iodine Radioisotopes; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Recombinant Proteins; Retinoid X Receptors; Tetrahydronaphthalenes; Thyroid Neoplasms; Thyroidectomy; Thyrotropin; Thyroxine; Triiodothyronine	2006
Phase II trial of bexarotene capsules in patients with advanced non-small-cell lung cancer after failure of two or more previous therapies. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Oct-20, Volume: 24, Issue:30 Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anticarcinogenic Agents; Bexarotene; Capsules; Carcinoma, Non-Small-Cell Lung; Exanthema; Female; Humans; Hypertriglyceridemia; Lung Neoplasms; Male; Middle Aged; Pleural Effusion; Survival Analysis; Tetrahydronaphthalenes	2006
A proof-of-principle clinical trial of bexarotene in patients with non-small cell lung cancer. Clinical cancer research : an official journal of the American Association for Cancer Research, 2007, Mar-15, Volume: 13, Issue:6 Topics: Antineoplastic Agents; Bexarotene; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Humans; Lung Neoplasms; Pilot Projects; Postoperative Period; Premedication; Tetrahydronaphthalenes; Tumor Cells, Cultured	2007
Bexarotene-induced hypothyroidism: bexarotene stimulates the peripheral metabolism of thyroid hormones. The Journal of clinical endocrinology and metabolism, 2007, Volume: 92, Issue:7 Topics: Aged; Anticarcinogenic Agents; Bexarotene; Drug Evaluation, Preclinical; Female; Humans; Hypothyroidism; Lung Neoplasms; Male; Middle Aged; Retinoid X Receptors; Tetrahydronaphthalenes; Thyroid Hormones; Thyroid Neoplasms; Thyrotropin; Thyroxine; Triiodothyronine	2007
Phase III trial comparing carboplatin, paclitaxel, and bexarotene with carboplatin and paclitaxel in chemotherapy-naive patients with advanced or metastatic non-small-cell lung cancer: SPIRIT II. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Apr-10, Volume: 26, Issue:11 Topics: Antineoplastic Combined Chemotherapy Protocols; Bexarotene; Carboplatin; Carcinoma, Non-Small-Cell Lung; Drug Administration Schedule; Humans; Hypertriglyceridemia; Lung Neoplasms; Male; Middle Aged; Neoplasm Transplantation; Paclitaxel; Survival Analysis; Tetrahydronaphthalenes	2008
Randomized phase III trial comparing bexarotene (L1069-49)/cisplatin/vinorelbine with cisplatin/vinorelbine in chemotherapy-naive patients with advanced or metastatic non-small-cell lung cancer: SPIRIT I. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Apr-10, Volume: 26, Issue:11 Topics: Antineoplastic Combined Chemotherapy Protocols; Bexarotene; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cisplatin; Disease Progression; Female; Humans; Hypertriglyceridemia; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Survival Analysis; Survival Rate; Tetrahydronaphthalenes; Triglycerides; Vinblastine; Vinorelbine	2008
Multi-institutional phase I/II trial of oral bexarotene in combination with cisplatin and vinorelbine in previously untreated patients with advanced non-small-cell lung cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, May-15, Volume: 19, Issue:10 Topics: Administration, Oral; Adult; Aged; Anticarcinogenic Agents; Antineoplastic Combined Chemotherapy Protocols; Bexarotene; Carcinoma, Non-Small-Cell Lung; Cisplatin; Drug Administration Schedule; Female; Humans; Karnofsky Performance Status; Lung Neoplasms; Male; Middle Aged; Survival Analysis; Tetrahydronaphthalenes; Vinblastine; Vinorelbine	2001

Other Studies

21 other study(ies) available for bexarotene and Lung Neoplasms

Article	Year
The novel rexinoid MSU-42011 is effective for the treatment of preclinical Kras-driven lung cancer. Scientific reports, 2020, 12-17, Volume: 10, Issue:1 Topics: Animals; Anticarcinogenic Agents; Apoptosis; Bexarotene; Carcinogens; Cell Line, Tumor; Cell Proliferation; Disease Models, Animal; Gene Expression Regulation, Neoplastic; Hepatocytes; Humans; Immunohistochemistry; Immunomodulation; Lung Neoplasms; Mice; Molecular Structure; Proto-Oncogene Proteins p21(ras); Retinoid X Receptors; Sterol Regulatory Element Binding Proteins; Tetrahydronaphthalenes; Tumor Microenvironment; Xenograft Model Antitumor Assays	2020
Bexarotene inhibits the viability of non-small cell lung cancer cells via slc10a2/PPARγ/PTEN/mTOR signaling pathway. BMC cancer, 2018, 04-11, Volume: 18, Issue:1 Topics: Apoptosis; Bexarotene; Biomarkers; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Movement; Cell Proliferation; Gene Expression; Humans; Lung Neoplasms; Organic Anion Transporters, Sodium-Dependent; PPAR gamma; PTEN Phosphohydrolase; Signal Transduction; Symporters; TOR Serine-Threonine Kinases	2018
Testing Novel Pyrimidinyl Rexinoids: A New Paradigm for Evaluating Rexinoids for Cancer Prevention. Cancer prevention research (Philadelphia, Pa.), 2019, Volume: 12, Issue:4 Topics: Animals; Anti-Inflammatory Agents; Antineoplastic Agents; Apoptosis; Bexarotene; Cell Proliferation; Female; Humans; Lung Neoplasms; Macrophages; Mice; Mice, Inbred A; Tetrahydronaphthalenes; Tumor Cells, Cultured; Xenograft Model Antitumor Assays	2019
Dual targeting of retinoid X receptor and histone deacetylase with DW22 as a novel antitumor approach. Oncotarget, 2015, Volume: 6, Issue:12 Topics: Aged; Animals; Antineoplastic Agents; Bexarotene; Breast Neoplasms; Cell Differentiation; Cell Line, Tumor; Cell Movement; Cyclin-Dependent Kinase Inhibitor p21; Drug Screening Assays, Antitumor; Female; Gene Expression Regulation, Neoplastic; Gene Silencing; Histone Deacetylase 1; Histones; HL-60 Cells; Human Umbilical Vein Endothelial Cells; Humans; Hydroxamic Acids; Lung Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, SCID; Middle Aged; Neoplasm Invasiveness; Neoplasm Transplantation; Neovascularization, Pathologic; Retinoid X Receptor alpha; RNA, Small Interfering; Tetrahydronaphthalenes; Up-Regulation; Vascular Endothelial Growth Factor A	2015
Morphology, in vivo distribution and antitumor activity of bexarotene nanocrystals in lung cancer. Drug development and industrial pharmacy, 2017, Volume: 43, Issue:1 Topics: Animals; Anticarcinogenic Agents; Bexarotene; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Delivery Systems; Female; Humans; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Microscopy, Electron, Transmission; Nanoparticles; Random Allocation; Tetrahydronaphthalenes; Tissue Distribution; Tumor Burden	2017
UBE1L causes lung cancer growth suppression by targeting cyclin D1. Molecular cancer therapeutics, 2008, Volume: 7, Issue:12 Topics: Anticarcinogenic Agents; Bexarotene; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cyclin D1; Cycloheximide; Cytokines; Humans; Ki-67 Antigen; Lung Neoplasms; Models, Biological; Plasmids; Retinoid X Receptors; Tetrahydronaphthalenes; Ubiquitin-Activating Enzymes; Ubiquitins	2008
Preventive effects of bexarotene and budesonide in a genetically engineered mouse model of small cell lung cancer. Cancer prevention research (Philadelphia, Pa.), 2009, Volume: 2, Issue:12 Topics: Adenoviridae; Animals; Anti-Inflammatory Agents; Anticarcinogenic Agents; Apoptosis; Bexarotene; Budesonide; Cell Proliferation; Disease Models, Animal; Female; Genetic Engineering; Immunoenzyme Techniques; In Situ Nick-End Labeling; Integrases; Lung Neoplasms; Male; Mice; Mice, Inbred A; Retinoblastoma Protein; Small Cell Lung Carcinoma; Tetrahydronaphthalenes; Tumor Suppressor Protein p53	2009
Aerosolized bexarotene inhibits lung tumorigenesis without increasing plasma triglyceride and cholesterol levels in mice. Cancer prevention research (Philadelphia, Pa.), 2011, Volume: 4, Issue:2 Topics: Administration, Inhalation; Animals; Anticarcinogenic Agents; Apoptosis; Bexarotene; Cell Proliferation; Cholesterol; Female; Immunoenzyme Techniques; Lung Neoplasms; Mice; Mice, Inbred A; Tetrahydronaphthalenes; Triglycerides	2011
NSCLC drug targets acquire new visibility. Journal of the National Cancer Institute, 2011, Mar-02, Volume: 103, Issue:5 Topics: Antineoplastic Agents; Benzenesulfonates; Benzimidazoles; Bexarotene; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Crizotinib; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Molecular Targeted Therapy; Mutation; Niacinamide; Oncogene Proteins, Fusion; Phenylurea Compounds; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrazoles; Pyridines; Quinazolines; Randomized Controlled Trials as Topic; Sorafenib; Tetrahydronaphthalenes; Treatment Outcome	2011
Identification of polymorphisms associated with hypertriglyceridemia and prolonged survival induced by bexarotene in treating non-small cell lung cancer. Anticancer research, 2011, Volume: 31, Issue:6 Topics: Bexarotene; Carcinoma, Non-Small-Cell Lung; Case-Control Studies; Clinical Trials, Phase III as Topic; DNA; Female; Genetic Predisposition to Disease; Humans; Hypertriglyceridemia; Lung Neoplasms; Male; Middle Aged; Polymorphism, Single Nucleotide; Tetrahydronaphthalenes	2011
Prevention of mouse lung tumors by combinations of chemopreventive agents using concurrent and sequential administration. Anticancer research, 2011, Volume: 31, Issue:10 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Bexarotene; Body Weight; Budesonide; Chemoprevention; Female; Hydroxamic Acids; Lung Neoplasms; Mice; Tetrahydronaphthalenes; Vorinostat	2011
A selective retinoid X receptor agonist bexarotene (Targretin) prevents and overcomes acquired paclitaxel (Taxol) resistance in human non-small cell lung cancer. Clinical cancer research : an official journal of the American Association for Cancer Research, 2004, Dec-15, Volume: 10, Issue:24 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; Bexarotene; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; Humans; Lung Neoplasms; Male; Mice; Mice, Nude; Mutation; Paclitaxel; Retinoid X Receptors; Survival Rate; Tetrahydronaphthalenes; Transplantation, Heterologous; Tumor Cells, Cultured	2004
The retinoid X receptor agonist bexarotene (Targretin) synergistically enhances the growth inhibitory activity of cytotoxic drugs in non-small cell lung cancer cells. Lung cancer (Amsterdam, Netherlands), 2005, Volume: 50, Issue:1 Topics: Animals; Anticarcinogenic Agents; Antineoplastic Agents, Phytogenic; Bexarotene; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Drug Interactions; Humans; Lung Neoplasms; Male; Mice; Mice, Nude; Paclitaxel; Tetrahydronaphthalenes; Transplantation, Heterologous; Vinblastine; Vinorelbine	2005
Prevention of lung cancer progression by bexarotene in mouse models. Oncogene, 2006, Mar-02, Volume: 25, Issue:9 Topics: Adenocarcinoma; Adenoma; Animals; Anticarcinogenic Agents; Bexarotene; Carcinogens; Carcinoma, Non-Small-Cell Lung; Disease Models, Animal; Disease Progression; Genes, p53; Genes, ras; Humans; Lung Neoplasms; Mice; Mice, Transgenic; Tetrahydronaphthalenes; Urethane	2006
Prevention of mouse lung tumors by targretin. International journal of cancer, 2006, May-01, Volume: 118, Issue:9 Topics: Animals; Anticarcinogenic Agents; Bexarotene; Chemoprevention; Dose-Response Relationship, Drug; Female; Lung Neoplasms; Mice; Neoplasms, Experimental; Nitrosamines; Tetrahydronaphthalenes; Urethane	2006
Promising results achieved with a combination of chemotherapy and two retinoids in patients with advanced non-small-cell lung cancer. Lung cancer (Amsterdam, Netherlands), 2006, Volume: 51, Issue:3 Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bexarotene; Biological Availability; Carcinoma, Non-Small-Cell Lung; Female; Humans; Lung Neoplasms; Male; Middle Aged; Survival Rate; Tetrahydronaphthalenes; Treatment Outcome; Tretinoin	2006
A selective retinoid X receptor agonist bexarotene (LGD1069, targretin) inhibits angiogenesis and metastasis in solid tumours. British journal of cancer, 2006, Mar-13, Volume: 94, Issue:5 Topics: Animals; Anticarcinogenic Agents; Bexarotene; Cell Line, Tumor; Cell Movement; Endothelial Cells; Humans; Lung Neoplasms; Mice; Neoplasm Metastasis; Neovascularization, Pathologic; Retinoid X Receptors; Tetrahydronaphthalenes; Transplantation, Heterologous; Umbilical Cord	2006
The retinoid X receptor-selective ligand, LGD1069, inhibits tumor-induced angiogenesis via suppression of VEGF in human non-small cell lung cancer. Cancer letters, 2007, Apr-08, Volume: 248, Issue:1 Topics: Animals; Anticarcinogenic Agents; Bexarotene; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Dose-Response Relationship, Drug; Enzyme Activation; Gene Expression Regulation, Neoplastic; HT29 Cells; Humans; Immunohistochemistry; JNK Mitogen-Activated Protein Kinases; Lung Neoplasms; Mice; Mice, Nude; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Neovascularization, Pathologic; Platelet Endothelial Cell Adhesion Molecule-1; Retinoid X Receptors; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tetrahydronaphthalenes; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays	2007
Bexarotene (LGD1069, Targretin), a selective retinoid X receptor agonist, prevents and reverses gemcitabine resistance in NSCLC cells by modulating gene amplification. Cancer research, 2007, May-01, Volume: 67, Issue:9 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Bexarotene; Carcinoma, Non-Small-Cell Lung; Cell Growth Processes; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Drug Synergism; Female; Gemcitabine; Gene Amplification; Humans; Lung Neoplasms; Mice; Mice, Nude; Retinoid X Receptors; Tetrahydronaphthalenes; Xenograft Model Antitumor Assays	2007
Modulation by bexarotene of mRNA expression of genes in mouse lung tumors. Molecular carcinogenesis, 2008, Volume: 47, Issue:3 Topics: Administration, Oral; Animals; Anticarcinogenic Agents; Bexarotene; DNA Methyltransferase 3A; Drug Administration Schedule; Female; Gene Expression Regulation, Neoplastic; Intercellular Signaling Peptides and Proteins; Lung Neoplasms; Mice; Mice, Inbred A; Peptides; Pulmonary Surfactant-Associated Protein C; RNA, Messenger; Tetrahydronaphthalenes; Tumor Burden; Urethane; Uteroglobin	2008
[LGD1069: an antagonist to the X retinoid receptor]. Bulletin du cancer, 2000, Volume: 87, Issue:3 Topics: Animals; Anticarcinogenic Agents; Bexarotene; Cells, Cultured; Clinical Trials as Topic; Dimerization; Drug Eruptions; Drug Evaluation; Drug Screening Assays, Antitumor; Humans; Lung Neoplasms; Lymphoma, T-Cell; Mice; Rats; Receptors, Retinoic Acid; Retinoid X Receptors; Skin Neoplasms; Structure-Activity Relationship; Tetrahydronaphthalenes; Transcription Factors; Transcriptional Activation	2000